Latest / Glaucoma, Vision & Longevity: Supplements & Science / Brain Imaging Biomarkers and Plasticity in Glaucoma

Transcript

Brain Imaging Biomarkers and Plasticity in Glaucoma · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Glaucoma affects more than the eye.
• 0:02
  SPEAKER_00: Glaucoma is best known as a disease of the optic nerve and retina, but modern brain scans show it also involves the brain's vision centers.
• 0:11
  SPEAKER_00: Studies using MRI have found that people with glaucoma often have smaller brain structures and weaker connections in visual areas compared to healthy people.
• 0:21
  SPEAKER_00: For example, a review in Frontiers in Neuroscience found thinner cortex in visual brain regions, lower volume in V1 and other visual areas, and abnormal blood oxygen signals on fMRI and glaucoma patients.
• 0:35
  SPEAKER_00: These findings suggest that damage in the eye can travel backwards along the visual pathway, a process known as transsynaptic degeneration.
• 0:43
  SPEAKER_00: In other words, when retinal ganglion cells die in glaucoma, connected neurons in the lateral genicate nucleus, LGN, and visual cortex can shrink or lose function too.
• 0:55
  SPEAKER_00: Doctors and researchers use advanced MRI techniques to track these changes.
• 1:00
  SPEAKER_00: One method is diffusion tensor imaging, DTI, which traces the brain's white matter fiber tracts.
• 1:06
  SPEAKER_00: DTI has revealed rarefaction, thinning, of the optic radiations, the fibers from the LGN to visual cortex in glaucoma patients, reflecting loss of nerve fibers.
• 1:16
  SPEAKER_00: Graph theory analysis of DTI data even shows wide-range network changes.
• 1:20
  SPEAKER_00: Glaucoma patients have altered connectivity not just in visual areas, but also in regions for movement and emotion.
• 1:27
  SPEAKER_00: In functional MRI, FMRI scans, which measure brain activity, glaucoma patients often show reduced activation in the primary visual cortex, V1, when viewing images, and weaker functional connections between visual areas.
• 1:42
  SPEAKER_00: In short, the brain imaging paints a consistent picture.
• 1:45
  SPEAKER_00: Glaucoma is associated with degeneration of the central visual pathway and disruption of normal network activity.
• 1:53
  SPEAKER_00: MRI studies also measure cortical thickness, the thickness of the gray matter surface.
• 1:59
  SPEAKER_00: Several studies report that glaucoma patients have a thinner visual cortex.
• 2:03
  SPEAKER_00: For instance, one MRI study found that people with open-angle glaucoma had significantly lower V1 thickness and smaller LGN volumes compared to controls.
• 2:13
  SPEAKER_00: These structural losses correlated with vision.
• 2:16
  SPEAKER_00: In that study, thinner V1 and smaller LGN were tied to worse visual field scores, larger cup to disc ratio.
• 2:24
  SPEAKER_00: Interestingly, brain changes are not limited to vision areas.
• 2:28
  SPEAKER_00: Some patients show thinning in non-visual regions like the frontal pole and amygdala, which may relate to the stress or cognitive aspects of living with glaucoma.
• 2:37
  SPEAKER_00: Altogether, these results confirm that eye damage in glaucoma leads to measurable brain atrophy and thinning, especially in visual pathways.
• 2:46
  SPEAKER_00: Brain plasticity and reorganization.
• 2:49
  SPEAKER_00: The brain is not completely helpless in glaucoma.
• 2:52
  SPEAKER_00: There is evidence of neuroplasticity, reorganization that can help preserve function.
• 2:57
  SPEAKER_00: When retinal cells die, nearby neurons or other pathways may adapt.
• 3:01
  SPEAKER_00: Research in animals and patients shows that some retinal ganglion cells can recover function if treated early, and that the brain can adjust its wiring after long-term vision loss.
• 3:12
  SPEAKER_00: For example, one study of mice found young animals could regain full retinal nerve function days after a pressure-induced injury, whereas older mice took much longer.
• 3:23
  SPEAKER_00: In humans, vision tests often improve after lowering eye pressure in mild glaucoma, suggesting surviving neurons ramp up activity.
• 3:32
  SPEAKER_00: On a brain level, functional MRI and connectivity studies hint that undamaged parts of the visual network may increase their connectivity to compensate for lost input.
• 3:43
  SPEAKER_00: Specialized analyses, AI analysis, or advanced computational modeling are helping to spot subtle reorganization.
• 3:50
  SPEAKER_00: For example, DTI-based network models found that glaucoma patients show higher clustering, stronger local connectivity, in certain occipital regions, perhaps reflecting an attempt to reroute visual information.
• 4:03
  SPEAKER_00: Overall, imaging suggests the adult visual cortex retains some flexibility.
• 4:08
  SPEAKER_00: It can partially reorganize blood flow and synaptic connections after injury.
• 4:13
  SPEAKER_00: However, this plasticity has limits.
• 4:16
  SPEAKER_00: If the retinal loss is too severe or the disease is advanced, many neurons are gone and the cortex thinning becomes irreversible.
• 4:23
  SPEAKER_00: MRI biomarkers of resilience.
• 4:26
  SPEAKER_00: Researchers are now eager to find which brain changes predict better or worse outcomes.
• 4:31
  SPEAKER_00: The hope is to identify biomarkers, MRI features that indicate who is resilient, maintains vision, versus who might benefit most from therapy.
• 4:40
  SPEAKER_00: For instance, if a patient's visual cortex is still relatively thick and its connections largely intact on DTI MRI, they may have a reserve that could support recovery with treatment.
• 4:50
  SPEAKER_00: Conversely, early signs of LGN shrinkage or optic radiation damage might signal rapid progression.
• 4:57
  SPEAKER_00: Some candidate biomarkers have emerged from studies.
• 5:00
  SPEAKER_00: One approach is to correlate brain metrics with vision tests.
• 5:04
  SPEAKER_00: The network connectivity study mentioned above found that thinner retinal nerve fiber layer from OCTI scans was linked to abnormal connectivity in the amygdala and temporal lobe on MRI.
• 5:16
  SPEAKER_00: This suggests combining retinal imaging and brain scans could flag patients whose brains are keeping up with the damage.
• 5:24
  SPEAKER_00: Another study showed a tight correlation.
• 5:27
  SPEAKER_00: Eyes with worse visual field loss had thinner V1 cortex and smaller LGN on MRI.
• 5:33
  SPEAKER_00: In practice, a patient with preserved V1 thickness or high fidelity DTI pathways might be more likely to maintain vision if treated.
• 5:42
  SPEAKER_00: These ideas are still being tested, but the principle is that MRI measures of visual pathway integrity could one day help predict individual outcomes.
• 5:51
  SPEAKER_00: Fusion of eye and brain imaging.
• 5:53
  SPEAKER_00: To get the best picture of glaucoma, experts advocate multimodal imaging, combining eye tests and brain scans.
• 6:00
  SPEAKER_00: For example, optical coherence tomography, OCT, can precisely measure the retina's nerve layers, while MRI assesses the brain.
• 6:08
  SPEAKER_00: One recent study explicitly linked these.
• 6:10
  SPEAKER_00: It found associations between OCT measures like macular ganglion cell layer thickness and brain connectivity.
• 6:17
  SPEAKER_00: In that work, weaker connectivity in certain brain nodes went along with thinner retinal layers.
• 6:23
  SPEAKER_00: This kind of fusion could improve disease staging, knowing how advanced it is, and help select patients for neuroprotective treatments or rehabilitation.
• 6:33
  SPEAKER_00: In future clinical trials, doctors might require both OCT and brain MRI to choose patients whose brains have enough intact wiring to benefit from therapy.
• 6:42
  SPEAKER_00: Another practical example, combining visual field tests, functional eye exam with MRI-based biomarkers.
• 6:49
  SPEAKER_00: If a patient shows stable visual fields but MRI reveals worsening LGN atrophy, that might prompt earlier intervention.
• 6:57
  SPEAKER_00: Conversely, some patients with significant field loss might still have relatively strong brain networks and be good candidates for neuroenhancement techniques.
• 7:06
  SPEAKER_00: By bringing together ocular data, OCT, field tests, and neuroimaging, clinicians aim for a fuller assessment than either can provide alone.
• 7:15
  SPEAKER_00: Future directions, longitudinal studies, and rehabilitation.
• 7:19
  SPEAKER_00: Most MRI studies so far are snapshots of patients at one time.
• 7:24
  SPEAKER_00: The next big step is longitudinal research, following the same patients over months or years.
• 7:30
  SPEAKER_00: Such studies would track how brain imaging markers change over time, especially after interventions.
• 7:36
  SPEAKER_00: For instance, if a glaucoma patient undergoes a visual training program or starts a neuroprotective drug, we could see whether their MRI markers, like V1 thickness or connectivity, show positive changes.
• 7:48
  SPEAKER_00: Researchers suggest linking plasticity markers to rehab outcomes.
• 7:52
  SPEAKER_00: Do patients who show early signs of brain reorganization on fMRI end up gaining more vision with therapy?
• 7:59
  SPEAKER_00: Some clues are emerging.
• 8:01
  SPEAKER_00: A 2023 trial used virtual reality visual training in glaucoma patients.
• 8:06
  SPEAKER_00: After three months, the patients showed a slight increase in the thickness of the macular ganglion cell layer measured by OCT and improved sensitivity in the trained visual field area.
• 8:17
  SPEAKER_00: This provides proof of concept that training can induce structural and functional recovery.
• 8:22
  SPEAKER_00: The next question is whether MRI could predict or monitor such gains.
• 8:27
  SPEAKER_00: For example, one could imagine an fMRI before and after visual training.
• 8:32
  SPEAKER_00: Patients whose brain response in V1 improves might also have better vision outcomes.
• 8:37
  SPEAKER_00: Another angle is lifestyle.
• 8:39
  SPEAKER_00: Preliminary evidence, mostly from animal studies, suggests exercise and diet can boost retinal recovery.
• 8:46
  SPEAKER_00: It would be valuable to see if these general measures reflect in brain scans, e.g., preserved visual cortex thickness in exercising patients.
• 8:55
  SPEAKER_00: In short, doctors and scientists see a path forward, use advanced imaging over time to identify early brain plasticity signals and link them to vision test results.
• 9:05
  SPEAKER_00: This could validate targets for rehabilitation and guide personalized therapy.
• 9:10
  SPEAKER_00: Ultimately, the goal is a feedback loop.
• 9:12
  SPEAKER_00: Measure MRI biomarkers, apply a treatment or training, re-measure MRI and vision, and optimize recovery strategies based on what the brain imaging shows.
• 9:22
  SPEAKER_00: Conclusion: Growing evidence shows that glaucoma is a neurodegenerative disease affecting the entire visual pathway, not just the eye.
• 9:30
  SPEAKER_00: State-of-the-art MRI methods, DTI, FMRI, cortical thickness mapping, reveal retrograde degeneration from the eye back to the brain and hints of compensatory plasticity in visual cortex.
• 9:42
  SPEAKER_00: Identifying which MRI changes predict better outcomes, resilience biomarkers, is an active research goal.
• 9:48
  SPEAKER_00: Combining eye and brain imaging may improve disease staging and help match patients to new treatments.
• 9:55
  SPEAKER_00: Crucially, long-term studies will test whether imaging markers of brain plasticity actually translate into better vision after therapy.
• 10:04
  SPEAKER_00: This research promises to guide future rehabilitation approaches, from drugs to visual training, so patients with glaucoma can keep seeing better for longer.
• 10:14
  SPEAKER_00: All links to sources are available in the text version of this article.
• 10:18
  SPEAKER_00: You can find the full article at visualfieldtest.com.
• 10:22
  SPEAKER_00: Thanks for listening.
• 10:23
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.